MX2017017081A - Polimorfo de macrociclo de diarilo. - Google Patents
Polimorfo de macrociclo de diarilo.Info
- Publication number
- MX2017017081A MX2017017081A MX2017017081A MX2017017081A MX2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorph
- macrocycle
- diaryl
- polymorphs
- mammals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Esta divulgación se refiere a los polimorfos de (7S,13R,)-11-fluoro-7,13-dimetil-6,7,13,14-tetrahidro-1,15-etenop irazolo[4,3-f] [1,4,8,10]benzoxatriazaciclotridecin-4(5H)-ona que son útiles en el tratamiento de enfermedades, tales como cáncer, en mamíferos. Esta divulgación también se relaciona con composiciones que incluyen estos polimorfos y a métodos para usar dichas composiciones en el tratamiento de enfermedades, tales como el cáncer, en mamíferos, especialmente en los seres humanos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562188846P | 2015-07-06 | 2015-07-06 | |
US201562218672P | 2015-09-15 | 2015-09-15 | |
PCT/US2016/040972 WO2017007759A1 (en) | 2015-07-06 | 2016-07-05 | Diaryl macrocycle polymorph |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017017081A true MX2017017081A (es) | 2018-08-16 |
Family
ID=57685592
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017017081A MX2017017081A (es) | 2015-07-06 | 2016-07-05 | Polimorfo de macrociclo de diarilo. |
MX2021008145A MX2021008145A (es) | 2015-07-06 | 2017-12-20 | Polimorfo de macrociclo de diarilo. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008145A MX2021008145A (es) | 2015-07-06 | 2017-12-20 | Polimorfo de macrociclo de diarilo. |
Country Status (16)
Country | Link |
---|---|
US (4) | US10294242B2 (es) |
EP (1) | EP3319969B1 (es) |
JP (2) | JP6917974B2 (es) |
KR (1) | KR102623734B1 (es) |
CN (2) | CN108026108B (es) |
AU (1) | AU2016289454B2 (es) |
BR (1) | BR112018000297A2 (es) |
CA (1) | CA2990020C (es) |
FI (1) | FI3319969T3 (es) |
HK (1) | HK1254492A1 (es) |
IL (2) | IL256443B (es) |
LT (1) | LT3319969T (es) |
MX (2) | MX2017017081A (es) |
RU (1) | RU2765181C2 (es) |
WO (1) | WO2017007759A1 (es) |
ZA (1) | ZA201708436B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA121206C2 (uk) | 2014-01-24 | 2020-04-27 | Турнінґ Поінт Терапьютикс, Інк. | Діарильні макроцикли як модулятори протеїнкіназ |
ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
EP3733187A1 (en) * | 2015-07-21 | 2020-11-04 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
RU2019105587A (ru) | 2016-07-28 | 2020-08-28 | Тёрнинг Поинт Терапьютикс, Инк. | Макроциклические ингибиторы киназ |
TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
CN107586796B (zh) * | 2017-07-20 | 2021-08-06 | 暨明医药科技(苏州)有限公司 | (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法 |
UA126158C2 (uk) | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Макроциклічні сполуки і їх використання |
ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
WO2019201131A1 (zh) * | 2018-04-16 | 2019-10-24 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
MX2021004538A (es) | 2018-10-22 | 2021-09-10 | Esker Therapeutics Inc | Inhibidores de tyk2 y sus usos. |
US20220235070A1 (en) | 2019-05-21 | 2022-07-28 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
PE20220135A1 (es) * | 2019-06-19 | 2022-01-27 | Turning Point Therapeutics Inc | Polimorfos de un inhibidor de cinasas macrociclicas |
BR112022010278A2 (pt) | 2019-11-27 | 2022-10-04 | Turning Point Therapeutics Inc | Terapia combinada que envolve compostos macrocíclicos de diarila |
IL293208A (en) | 2019-11-27 | 2022-07-01 | Turning Point Therapeutics Inc | Combination therapy involving diaryl macrocyclic compounds |
EP4114530A4 (en) * | 2020-03-02 | 2024-04-17 | Turning Point Therapeutics Inc | THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS |
CN113620974B (zh) | 2020-05-08 | 2023-01-31 | 山东轩竹医药科技有限公司 | 大环类酪氨酸激酶抑制剂的晶型及其制备方法 |
CN112174982A (zh) * | 2020-09-10 | 2021-01-05 | 上海希迈医药科技有限公司 | 一种洛普替尼晶型及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9403639D0 (en) * | 1994-02-25 | 1994-04-13 | Boots Co Plc | Therapeutic agents |
AU2002322802A1 (en) * | 2001-07-27 | 2003-02-17 | Merck And Co., Inc. | Thrombin inhibitors |
AU2009288021B2 (en) | 2008-09-08 | 2015-06-18 | Merck Patent Gmbh | Macrocyclics pyrimidines as Aurora kinase inhibitors |
SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
ES2588504T3 (es) | 2008-10-22 | 2016-11-03 | Array Biopharma, Inc. | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como compuestos intermedios en la síntesis de inhibidores de TRK quinasa |
EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
SG10201506591TA (en) * | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
KR20140059236A (ko) | 2011-08-19 | 2014-05-15 | 머크 샤프 앤드 돔 코포레이션 | Hcv 프로테아제 억제제의 결정 형태 |
HUE027318T2 (en) | 2011-09-30 | 2016-10-28 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
MX350844B (es) | 2012-03-06 | 2017-09-22 | Pfizer | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas. |
JP6418949B2 (ja) * | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | イミダゾ[1,2−b]ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法 |
DK2834243T3 (en) | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
US10497029B2 (en) * | 2013-10-21 | 2019-12-03 | Disney Enterprises, Inc. | Systems and methods for facilitating brand integration within online content and promoting that online content |
UA121206C2 (uk) | 2014-01-24 | 2020-04-27 | Турнінґ Поінт Терапьютикс, Інк. | Діарильні макроцикли як модулятори протеїнкіназ |
ES2864839T3 (es) * | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
EP3733187A1 (en) * | 2015-07-21 | 2020-11-04 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
-
2016
- 2016-07-05 JP JP2018500582A patent/JP6917974B2/ja active Active
- 2016-07-05 CN CN201680051405.5A patent/CN108026108B/zh active Active
- 2016-07-05 AU AU2016289454A patent/AU2016289454B2/en active Active
- 2016-07-05 MX MX2017017081A patent/MX2017017081A/es unknown
- 2016-07-05 BR BR112018000297A patent/BR112018000297A2/pt not_active Application Discontinuation
- 2016-07-05 CA CA2990020A patent/CA2990020C/en active Active
- 2016-07-05 EP EP16821872.5A patent/EP3319969B1/en active Active
- 2016-07-05 RU RU2018104269A patent/RU2765181C2/ru active
- 2016-07-05 KR KR1020187002778A patent/KR102623734B1/ko active IP Right Grant
- 2016-07-05 FI FIEP16821872.5T patent/FI3319969T3/fi active
- 2016-07-05 CN CN202110623105.2A patent/CN113354653A/zh active Pending
- 2016-07-05 LT LTEPPCT/US2016/040972T patent/LT3319969T/lt unknown
- 2016-07-05 US US15/741,893 patent/US10294242B2/en active Active
- 2016-07-05 WO PCT/US2016/040972 patent/WO2017007759A1/en active Application Filing
-
2017
- 2017-12-12 ZA ZA2017/08436A patent/ZA201708436B/en unknown
- 2017-12-20 MX MX2021008145A patent/MX2021008145A/es unknown
- 2017-12-20 IL IL256443A patent/IL256443B/en active IP Right Grant
-
2018
- 2018-10-25 HK HK18113701.3A patent/HK1254492A1/zh unknown
-
2019
- 2019-04-08 US US16/378,095 patent/US20190233437A1/en not_active Abandoned
-
2020
- 2020-10-15 US US17/071,569 patent/US20210094974A1/en not_active Abandoned
-
2021
- 2021-04-16 JP JP2021069649A patent/JP7212713B2/ja active Active
- 2021-05-13 IL IL283184A patent/IL283184B2/en unknown
-
2022
- 2022-09-19 US US17/933,434 patent/US20230295184A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008145A (es) | Polimorfo de macrociclo de diarilo. | |
MX2018000718A (es) | Macrociclos de diarilo quirales y usos de los mismos. | |
MX2023010042A (es) | Polinucleotidos moduladores. | |
IL264049A (en) | Compounds, preparations and methods for treating the disease | |
PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
IL264156A (en) | Compounds, preparations and methods for treating the disease | |
PH12016502168B1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
MY193728A (en) | Muscarinic receptor agonists | |
UA118759C2 (uk) | Сполуки 3,4-дигідроізохінолін-2(1н)-ілу | |
PH12016502307B1 (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
WO2017214170A3 (en) | Baff-r antibodies and uses thereof | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
SG10201908881PA (en) | Fused bicyclic compounds for the treatment of disease | |
MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
WO2015044961A3 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases |